Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00489554
First received: June 20, 2007
Last updated: June 14, 2012
Last verified: June 2012
  Purpose

The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of Mexican infants with pneumococcal conjugate vaccine GSK 1024850A co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined vaccine (Infanrix hexa) and rotavirus vaccine (Rotarix) in children during the first 6 months of age.


Condition Intervention Phase
Pneumococcal Disease
Biological: Synflorix
Biological: Infanrix hexa
Biological: Rotarix
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Infanrix Hexa and Rotarix

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Antibody Concentrations Against Pneumococcal Vaccine Serotypes [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    Concentrations were expressed as geometric mean concentration (GMC). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

  • Antibody Concentrations Against Protein D [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    Concentrations were given as geometric mean concentration (GMC) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter.


Secondary Outcome Measures:
  • Opsonophagocytic Titer Against Pneumococcal Vaccine Serotypes [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

  • Number of Subjects With Anti-pneumococcal Vaccine Serotypes Antibody Concentrations Greater Than or Equal to 0.2 Microgram Per Milliliter [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

  • Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    Antibody concentrations were expressed as Geometric Mean Concentrations against pneumococcal cross-reactive serotypes 6A and 19A.

  • Opsonophagocytic Titer Against Pneumococcal Cross-reactive Serotypes [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

  • Number of Subjects Seropositive Against Vaccine Pneumococcal Serotypes [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

  • Number of Subjects Seropositive for Opsonic Titer Against Vaccine Pneumococcal Serotypes [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    Seropositivity was defined as an opsonic titer greater than or equal to 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

  • Number of Subjects Seropositive Against Cross-reactive Pneumococcal Serotypes [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

  • Number of Subjects Seropositive for Opsonic Titer Against Cross-reactive Pneumococcal Serotypes [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    Seropositivity was defined as anti-pneumococcal antibody opsonic titer greater than or equal to 8. The vaccine pneumococcal cross-reactive serotypes assessed include 6A and 19A.

  • Number of Subjects Seropositive for Anti-Protein D Antibodies [ Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5 ] [ Designated as safety issue: No ]
    Seropositivity was defined as antibody concentration greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter.

  • Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) [ Time Frame: Within 4 days following any vaccine dose ] [ Designated as safety issue: No ]
    Grade 3 redness and swelling was > 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful. Any was occurrence of any local symptom regardless of grade and whatever the number of injections.

  • Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs [ Time Frame: Within 4 days following any vaccine dose ] [ Designated as safety issue: No ]
    Any fever was defined as axillary temperature ≥ 37.5 degree centigrade (°C), grade 3 fever was axillary temperature > 39.5°C. Grade 3 drowsiness, irritability, and loss of appetite was general symptom which prevented normal everyday activities. Grade 3 diarrhea was ≥ 6 looser than normal stools/day and Grade 3 vomiting was ≥ 3 episodes of vomiting/day. Related was solicited general symptom considered by the investigator to have a causal relationship to study vaccination.

  • Number of Subjects Reporting Any Unsolicited AEs [ Time Frame: Within 31 days after any vaccine dose ] [ Designated as safety issue: No ]
    Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

  • Number of Subjects Reporting Any Serious Adverse Events (SAEs) [ Time Frame: Up to Month 5 ] [ Designated as safety issue: No ]
    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.


Enrollment: 230
Study Start Date: July 2007
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Synflorix Vaccine Group
Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.
Biological: Synflorix
Intramuscular injection, 3 doses.
Other Name: Pneumococcal conjugate vaccine GSK1024850A.
Biological: Infanrix hexa
Intramuscular injection, 3 doses.
Biological: Rotarix
Oral, 2 doses.

Detailed Description:

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

  Eligibility

Ages Eligible for Study:   6 Weeks to 12 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female subjects between and including 6-12 weeks of age at the time of the first vaccination.
  • Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Born after a gestation period of 36 to 42 weeks inclusive.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccines and ending 7 days after dose 1 and dose 2 and one month after dose 3.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
  • A family history of congenital or hereditary immunodeficiency.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, rotavirus and/or Streptococcus pneumoniae; with the exception of vaccines where the first dose may be given at birth within the first two weeks of life according to national recommendations (e.g. Hepatitis B and BCG).
  • History of, or intercurrent, diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type b disease.
  • Gastroenteritis within 7 days preceding the study vaccine administration (warrants deferral of the vaccination).
  • Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal (GI) tract, intussusception (IS) or other medical condition determined to be serious by the investigator.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • History of any neurological disorders or seizures.
  • Major congenital defects or serious chronic illness.
  • Acute disease at the time of enrolment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00489554

Locations
Mexico
GSK Investigational Site
Mexico, Mexico, 14080
GSK Investigational Site
Mexico city, Mexico, 14000
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications:
Schuerman L et al. Population variability of opsonophagocytic activity following 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate (PHiD-CV) vaccination more limited than antibody responses. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.
Schuerman L et al. Population variability in antibody responses following pneumococcal conjugate vaccination: experience with the non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00489554     History of Changes
Other Study ID Numbers: 109661
Study First Received: June 20, 2007
Results First Received: March 15, 2012
Last Updated: June 14, 2012
Health Authority: Mexico: Comisión de autorización Sanitaria - Dirección Ejecutiva de Autorización de Productos y Establecimientos

Keywords provided by GlaxoSmithKline:
Primary vaccination
Safety
Pneumococcal vaccine.
Pneumococcal disease
Immunogenicity

ClinicalTrials.gov processed this record on October 22, 2014